Cartalax

Cartalax is a synthetic short-chain peptide bioregulator with the amino acid sequence Ala-Glu-Asp (AED). It was developed within the peptide bioregulator research program associated with the St. Petersburg Institute of Bioregulation and Gerontology — the same program associated with related bioregulators such as Epitalon and Pinealon. It is a frequent subject of laboratory research and is supplied as a lyophilized powder for research use only.

In published in vitro and preclinical research, Cartalax has been studied in connection with peptide bioregulator theory — which proposes that short peptides derived from specific tissues act as tissue-specific regulators of gene expression — and in connection with fibroblast-associated signaling components in cell-culture models. These studies are conducted in cell-culture and animal research models. The findings derive from laboratory research and do not describe or imply any effect, benefit, or use in humans or animals.

Published literature has examined Cartalax across a range of cell-culture research models relating to short-peptide bioregulator biology. These reports reflect controlled laboratory conditions only and do not translate to dosing, treatment, or applications in any other context. Its mechanism is studied alongside related research bioregulators such as Epitalon, Thymalin, and BPC-157.

For further reading, see published research on peptide bioregulators on PubMed.

Product Specifications

For Research Use Only. Not for use in diagnostic, therapeutic, or human or animal in-vivo procedures. This product is sold exclusively for in-vitro laboratory research use. It is not a drug, dietary supplement, food, or cosmetic and has not been approved by the U.S. Food and Drug Administration for any use. Not intended to diagnose, treat, cure, mitigate, or prevent any disease. Not for human or animal consumption.